A one year open-label extension study to assess long term safety and tolerability of omalizumab treatment in poorly controlled moderate to severe allergic asthma patients who participated in the 52-week CIGE24IA04E1 study.
Phase of Trial: Phase III
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2007 New trial record.